CYP1A1 Ile462Val Polymorphism Is Associated with Cervical Cancer Risk in Caucasians Not Asians: A Meta-Analysis

Li-Na Wang1,2†, Fen Wang3†, Jie Liu2,4†, Ying-Hui Jin2,5, Cheng Fang5,6 and Xue-Qun Ren2,4*

1 Department of Gynaecology, Huaihe Hospital of Henan University, Kaifeng, China, 2 Center for Evidence-Based Medicine, Henan University, Kaifeng, China, 3 Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Nanchang University, Nanchang, China, 4 Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, China, 5 Center for Evidence-Based and Translation Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China, 6 Department of Evidence-Based Medicine and Clinical Epidemiology, The Second Clinical College, Wuhan University, Wuhan, China

Objective: Previous studies have reported that Ile462Val polymorphism in the gene Cytochrome P450 1A1 (CYP1A1) is associated with the risk of cervical cancer, but inconsistent results have emerged. Hence, we performed this updated and cumulative meta-analysis to ascertain a more accurate association between CYP1A1 Ile462Val polymorphism and risk of cervical cancer.

Methods: Studies involving the CYP1A1 Ile462Val polymorphism associated with cervical cancer risk were searched from the databases of PubMed, Scopus, ScienceDirect, and Chinese National Knowledge Infrastructure (CNKI). The strength of correlation was evaluated through calculating summary odds ratios (ORs) with the corresponding 95% confidence intervals (95% CIs). Subgroup analyses according to ethnicity, source of control and HWE were completed to further explore specific association between the polymorphism and the cancer risk.

Results: Altogether, 11 eligible case-control studies were ultimately encompassed into the current meta-analysis, with 1,932 patients and 2,039 healthy controls. The total analysis revealed a borderline relationship between CYP1A1 Ile462Val polymorphism and cervical cancer risk in general population. Interestingly, after subgroup analyses based on ethnicity and source of control, the polymorphism increased the susceptibility of cervical cancer in Caucasian (G vs. A: OR = 1.97, 95% CI = 1.24–3.13; GG vs. AA: OR = 3.24, 95% CI = 1.24–8.46; GA vs. AA: OR = 1.62, 95% CI = 1.25–2.10; GA+GG vs. AA: OR = 1.68, 95% CI = 1.16–2.43; GG vs. AA+GA: OR = 2.73, 95% CI = 1.05–7.10) and population-based (G vs. A: OR = 1.49, 95% CI = 1.10–2.02; GA vs. AA: OR = 1.41, 95% CI = 1.20–1.67; GA+GG vs. AA: OR = 1.40, 95% CI = 1.19–1.64) groups.

Conclusion: The CYP1A1 Ile462Val polymorphism may enhance the susceptibility to cervical cancer in Caucasian females.

Keywords: CYP1A1, Ile462Val, cervical cancer, polymorphism, risk
INTRODUCTION

Cervical cancer is followed by breast cancer, which is the first common cancer among women all over the world (Denslow et al., 2012). Besides the onset of cervical cancer was aged 15–49 years in developing countries (Forouzanfar et al., 2011). Cervical cancer is a major threat to woman’s health and quality of life, and is also the focal point and the difficulties for medical workers. Hence, to seek the risk factor and people who may be at high risk of cervical cancer for prevention is a significant and important work. As we know, smoking (Sood, 1991; Zeng et al., 2012) and human papillomavirus (HPV) infection (Patel et al., 2016) are the classical risk factor for cervical cancer. However, some women without smoking and HPV infection also got cervical cancer, why? That’s might be other factors play a role in the onset of cervical cancer, such as genetic background.

Cytchrome P450 (CYP) gene family and susceptibility to many cancers has been the most widely studied (Rodriguez-Anton et al., 2010). CYP1A1 is belonged to CYP gene family1, subfamily A, polypeptide 1 and has two major functional nonsynonymous polymorphisms: Mspl polymorphism m1 and Ile462Val polymorphism m2 (Sugawara et al., 2003). Ile462Val polymorphism is a heme-binding site due to the replacement of isoleucine (Ile) by valine (Val), which caused by G to A transition (A4889G) in exon 7 at codon 462, also called rs1048943. Moreover, we also searched through the references which were cited in the included studies to obtain additional relevant studies. Two independent authors searched and evaluated the eligibility of all studies and any disagreements were resolved by discussion.

Data Extraction

Two authors extracted the following data independently from all included studies: the last name of first author, year of publication, country of origin, ethnicity, sources of controls, sample sizes of cases and controls, genotype distribution in cases and controls, Hardy-Weinberg Equilibrium (HWE) for controls, and genotyping methods. If the HWE was not reported, we assessed it by the chi-square test and significance was set at $P < 0.05$ according to the genotype distribution in control. Disagreements were resolved by discussion.

Data Analysis

All analyses were conducted using the Comprehensive Meta-Analysis v2.2 software (Zeng et al., 2016a,b). First, the heterogeneity was evaluated using the $I^2$ test and Cochran Q test, both $I^2 < 50\%$ and $P > 0.1$ was considered acceptance heterogeneity and the fixed-effect model was chosen to pool single study; otherwise, the random-effect model was used. Subgroup analyses according to ethnicity, source of control, and HWE were conducted. Five genetic models were used for overall and subgroup analyses: G vs. A, GG vs. AA, GA vs. AA, (GA+GG) vs. AA, and GG vs. (AA+GA). The odds ratio (OR) and its 95% confidence interval (95%CI) were used to evaluate the pooled effect size. Sensitivity analysis was performed more, subgroup and sensitivity analyses were conducted to further ascertain such relationship.

MATERIALS AND METHODS

Ligibility Criteria

Any study was considered eligible if it met all of the following criteria: (1) contain information investigated the association between CYP1A1 Ile462Val polymorphism and risk of cervical cancer; (2) as a cohort or case-control design; (3) both cases and controls were clearly diagnosed and all controls were healthy subjects or tissues; (4) included information that allowed for calculation of the odds ratios (ORs) and 95% confidence intervals (CIs). The study investigated the cervical dysplasia, cervical intraepithelial neoplasia (CIN), or cervical squamous intraepithelial lesions (CSIL) was excluded. If any publication involved the same subjects, we compared them according to the population, exposure, control, and study period and chosen the more comprehensive one.

Literature Search

The PubMed, Scopus, ScienceDirect, and Chinese National Knowledge Infrastructure (CNKI) databases were searched for relevant studies that were published up to January 10, 2017. The search strategy included usage of the following key words: cervical, cervix, cancer, carcinoma, CYP1A1, cytochrome P-450, cytchrome P450, polymorphism, Ile462Val, A2455G, and rs1048943. More than ten case-control studies, and found that CYP1A1 Ile462Val polymorphism was associated with increased risk of cervical cancer in general populations. Besides, ethnic subgroup analyses showed a significant association was found in Caucasians but not in Asians (Yang et al., 2012; Wu et al., 2013; Qin et al., 2014; Wang et al., 2015), however, they obtained inconsistent results and with some deficiency (Table 1). For example, the meta-analysis performed by Yang et al. was conducted in 2012 involving ten case-control studies, and found that CYP1A1 Ile462Val polymorphism was associated with increased risk of cervical cancer in general populations. Moreover, several new original studies (Abbas et al., 2014; Roszak et al., 2014; Li et al., 2016) on this topic were published since then. The recent meta-analysis by Wang et al. pooled the data of 8 case-control studies and indicated the CYP1A1 Ile462Val polymorphism might be a risk factor for cervical cancer (Wang et al., 2015). Since data extracted from two articles (Sugawara et al., 2003; Joseph et al., 2006) were repeatedly included in the meta-analysis, six case-control studies were actually included. Also, due to different inclusion criteria and uneven sample sizes, several meta-analyses (Wu et al., 2013; Qin et al., 2014) presented opposite conclusions. Additionally, subgroup analyses by ethnicity could not be performed due to limited number of studies.

Thus, we identified relevant published reports through a systematic search strategy, and performed this updated and cumulative meta-analysis to reappraise between CYP1A1 Ile462Val polymorphism and risk of cervical cancer. What's
TABLE 1 | Characteristics of previous published meta-analyses on CYP1A1 Ile462Val polymorphism and cervical cancer risk.

| References | Search databases | End of search | Included studies | Study number | Topic |
|------------|-----------------|---------------|-----------------|--------------|-------|
| Sergentanis et al., 2012 | MEDLINE | October, 2010 | Sugawara et al., 2003; Joseph et al., 2006; Taskiran et al., 2006; Gutman et al., 2009 | 4 case–control studies | MapI and Ile462Val polymorphisms and cervical cancer risk |
| Yang et al., 2012 | PubMed, Embase, and CBM | May, 2012 | Sugawara et al., 2003; Huang et al., 2006; Joseph et al., 2006; Taskiran et al., 2006; Gutman et al., 2009; Zhang, 2009, 2011; Geng et al., 2010; Ding et al., 2011; Shi et al., 2011 | 10 case–control studies | CYP1A1 Ile462Val polymorphism and cervical cancer risk |
| Wu et al., 2013 | PubMed | December 31, 2012 | Sugawara et al., 2003; Joseph et al., 2006; Gutman et al., 2009 | 3 case–control studies | MapI and Ile462Val polymorphisms and overall cancer risk |
| Qin et al., 2014 | PubMed, ISI, and EMBASE | April 15, 2013 | Sugawara et al., 2003; Joseph et al., 2006; Taskiran et al., 2006; Gutman et al., 2009 | 4 case–control studies | CYP1A1 Ile462Val polymorphism and cancer risk |
| Wang et al., 2015 | PubMed and Embase | June, 2014 | Sugawara et al., 2003; Joseph et al., 2006; Taskiran et al., 2006; Gutman et al., 2009; Abbas et al., 2014; Roszak et al., 2014 | 8 case–control studies | 42 SNPs with genetic risk for cervical cancer |

RESULTS

Study Selection and Characteristics

Figure 1 shows the study selection process. The primary search yielded potentially related publications and finally 11 case-control studies involving 1,932 patients and 2,039 healthy controls were included (Sugawara et al., 2003; Huang et al., 2006; Joseph et al., 2006; Gutman et al., 2009; Zhang, 2009, 2011; Ding et al., 2011; Shi et al., 2011; Abbas et al., 2014; Roszak et al., 2014; Li et al., 2016). Of these 11 case-control studies, four dealt with probands of Caucasian origin (Joseph et al., 2006; Gutman et al., 2009; Abbas et al., 2014; Roszak et al., 2014) and seven referred to Asian origin (Sugawara et al., 2003; Huang et al., 2006; Zhang, 2009, 2011; Ding et al., 2011; Shi et al., 2011; Li et al., 2016); five studies were out of Hardy Weinberg Equilibrium (HWE) (Huang et al., 2006; Zhang, 2009; Ding et al., 2011; Shi et al., 2011; Abbas et al., 2014). Table 2 lists the main characteristics of identified studies.

Meta-Analysis Results

Table 3 demonstrates the results of overall and subgroup analyses. Overall, the association between CYP1A1 Ile462Val polymorphism and risk of cervical cancer was evaluated under five genetic models (G vs. A: OR = 1.27, 95% CI = 0.95–1.69, Figure 2; GG vs. AA: OR = 1.54, 95% CI = 0.87–2.74; GA vs. AA: OR = 1.27, 95% CI = 0.92–1.76; GA+GG vs. AA: OR = 1.25, 95% CI = 0.90–1.73; GG vs. AA+GA: OR = 1.31, 95% CI = 0.77–2.21), respectively. Sensitivity analysis indicated that the overall analysis was influenced only by Huang’s study (Figure 3), which indicated that the results were robust. Moreover, cumulative meta-analysis was conducted by adding one study at a time in the order of publication year. The results showed that evidence of the effect of CYP1A1 Ile462Val polymorphism on cervical cancer incidence was stable during the cumulative meta-analysis, but the CIs became increasing narrower (Figure 4). In total analysis, the association between CYP1A1 Ile462Val polymorphism and cervical cancer incidence is borderline and may indicate a role of this variant.

In the subgroup analysis for ethnicity, no significant association was found in Asians under any genetic models, but significantly increased risk was observed in Caucasians under all contrasts (G vs. A: OR = 1.97, 95% CI = 1.24–3.13; GG vs. AA: OR = 1.97, 95% CI = 1.24–3.13).
TABLE 2 | Main characteristics of studies included in this meta-analysis.

| References        | Country (Ethnicity) | Sample size | Genotype distribution (Case) | Genotype distribution (Control) | Source of control | Genotyping method | HWE |
|-------------------|---------------------|-------------|-----------------------------|--------------------------------|-------------------|------------------|------|
|                    |                     |             | Cases| AA | AG | GG | A | G | AA | AG | GG | A | G |
| Sugawara et al., 2003 | Japan (Asian)       | 75          | 31 | 48 | 27 | 0 | 123 | 27 | 21 | 10 | 0 | 52 | 10 |
| Huang et al., 2006 | China (Asian)       | 113         | 113 | 36 | 62 | 1 | 134 | 64 | 14 | 95 | 1 | 123 | 97 |
| Joseph et al., 2006 | India (Caucasian)   | 147         | 165 | 91 | 45 | 11 | 227 | 67 | 136 | 26 | 3 | 298 | 32 |
| Gutman et al., 2009 | Israel (Caucasian)  | 43          | 123 | 29 | 14 | 0 | 72 | 14 | 85 | 31 | 5 | 201 | 41 |
| Zhang, 2009        | China (Asian)       | 50          | 30 | 14 | 26 | 10 | 54 | 34 | 17 | 7 | 6 | 41 | 19 |
| Shi et al., 2011   | China (Asian)       | 176         | 112 | 34 | 121 | 21 | 189 | 163 | 32 | 76 | 4 | 140 | 84 |
| Ding et al., 2011  | China (Asian)       | 280         | 280 | 72 | 129 | 79 | 273 | 287 | 83 | 100 | 97 | 266 | 294 |
| Zhang, 2011        | China (Asian)       | 32          | 114 | 14 | 13 | 3 | 41 | 19 | 34 | 51 | 17 | 119 | 85 |
| Abbas et al., 2014 | India (Caucasian)   | 200         | 208 | 110 | 84 | 6 | 304 | 96 | 114 | 65 | 2 | 347 | 69 |
| Roszak et al., 2014 | Poland (Caucasian) | 456         | 495 | 415 | 41 | 0 | 871 | 82 | 466 | 29 | 0 | 961 | 29 |
| Li et al., 2016    | China (Asian)       | 360         | 368 | 199 | 141 | 20 | 539 | 181 | 217 | 135 | 16 | 569 | 167 |

PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; HWE, Hardy-Weinberg equilibrium.

TABLE 3 | Meta-analysis results on the relationship of CYP1A1 Ile462Val polymorphism with cervical cancer risk.

| Total and subgroups | Trails | G vs. A | OR (95%CI) | I² (%) | GG vs. AA | OR (95%CI) | I² (%) | GA vs. AA | OR (95%CI) | I² (%) | GA+GG vs. AA | OR (95%CI) | I² (%) | GG vs. (AA+GA) | OR (95%CI) | I² (%) |
|---------------------|--------|---------|-------------|--------|-----------|-------------|--------|-----------|-------------|--------|-------------|-------------|--------|----------------|-------------|--------|
| Total               | 11     | 1.27 (0.95–1.69) | 81.67 | 54.99 | 1.27 (0.92–1.76) | 72.99 | 1.25 (0.90–1.73) | 75.05 | 1.31 (0.77–2.21) | 52.36 |
| ETHNICITY           |        |         |             |        |           |             |        |           |             |        |             |             |        |               |             |        |
| Asian               | 7      | 1.00 (0.79–1.26) | 58.5 | 51.69 | 1.08 (0.66–1.75) | 78.88 | 1.04 (0.66–1.64) | 78.07 | 0.92 (0.69–1.22) | 44.89 |
| Caucasian           | 4      | 1.97 (1.24–3.13) | 75.81 | 42.09 | 1.62 (1.25–2.10) | 22.1 | 1.68 (1.16–2.43) | 50.26 | 2.73 (1.05–7.10) | 36.39 |
| SOURCE OF CONTROL   |        |         |             |        |           |             |        |           |             |        |             |             |        |               |             |        |
| HB                  | 3      | 0.76 (0.48–1.21) | 50.72 | 35.54 | 0.85 (0.18–4.02) | 89.44 | 0.77 (0.18–3.22) | 89.18 | 0.80 (0.35–1.81) | 0 |
| PB                  | 8      | 1.49 (1.10–2.02) | 80.72 | 64.4 | 1.41 (1.20–1.67) | 1.64 | 1.40 (1.19–1.64) | 33.69 | 1.61 (0.79–3.28) | 68.66 |
| HWE                 |        |         |             |        |           |             |        |           |             |        |             |             |        |               |             |        |
| No                  | 5      | 1.11 (0.79–1.56) | 76.56 | 57.43 | 1.22 (0.63–2.34) | 85 | 1.17 (0.63–2.15) | 84.31 | 1.38 (0.65–2.96) | 57 |
| Yes                 | 6      | 1.42 (0.87–2.33) | 84.29 | 63.86 | 1.36 (0.97–1.91) | 50.6 | 1.34 (0.91–1.98) | 64.31 | 1.24 (0.49–3.14) | 52.09 |

OR = 3.24, 95% CI = 1.24–8.46; GA vs. AA: OR = 1.62, 95% CI = 1.25–2.10; GA+GG vs. AA: OR = 1.68, 95% CI = 1.16–2.43; GG vs. AA+GA: OR = 2.73, 95% CI = 1.05–7.10. After stratified analysis by source of controls, significant results were found in population-based controls (G vs. A: OR = 1.49, 95% CI = 1.10–2.02; GA vs. AA: OR = 1.41, 95% CI = 1.20–1.67; GA+GG vs. AA: OR = 1.40, 95% CI = 1.19–1.64). No significant association existed in the studies conforming to HWE or deviating from HWE under all five genetic models (Table 3).

Publication Bias
As shown in Figure 5, no obvious publication bias was found. The Egger's test also showed no evidence of publication bias (G vs. A: P = 0.68; GG vs. AA: P = 0.57; GA vs. AA: P = 0.92; GA+GG vs. AA: P = 0.81; GG vs. AA+GA: P = 0.26).

DISCUSSION
Cervical cancer is the second most common cancer among women worldwide, frequently occurring in developing countries in particular (Forouzanfar et al., 2011; Denslow et al., 2012). To date, the pathogenesis of cervical cancer has not been identified utterly, but a few risk factors have been confirmed, including human papilloma virus (HPV) infection, smoking, multiparity and long duration of oral contraceptive use (Zeng...
et al., 2012; Patel et al., 2016). Currently, the complex interaction of environmental and genetic factors is also proposed to possibly conduce to the occurrence of cervical cancer.

Cytochrome P450 1A1 (CYP1A1) is a member of the CYP1 family and participates in the metabolic activation of structurally diverse xenobiotics and endobiotics (Rodriguez-Antona et al., 2010). So far, numerous studies have been conducted on the association between CYP1A1 Ile462Val polymorphism and the susceptibility to cervical cancer, but the conclusions are not unanimous (Sugawara et al., 2003; Huang et al., 2006; Abbas et al., 2014). A few meta-analyses (Sergentanis et al., 2012; Yang et al., 2012; Wu et al., 2013; Qin et al., 2014; Wang et al., 2015) were also conducted to figure out the influence of CYP1A1 Ile462Val polymorphism on cervical cancer susceptibility. However, due to different inclusive criteria and uneven sample sizes, these reports presented different conclusions. Although most of them indicated that CYP1A1 Ile462Val polymorphism might be a risk factor for cervical cancer, the effects of the polymorphism on different ethnic groups were not fully clarified. Therefore, we conducted this cumulative meta-analysis to obtain accurate and up-to-date estimates of the association between the CYP1A1 Ile462Val polymorphism and cervical cancer susceptibility.

In the current meta-analysis, we incorporated 11 case-control studies involving 1,932 patients and 2,039 healthy
controls to statistically discuss this issue. According to our inclusion criteria, the controls clearly diagnosed as healthy subjects or tissues were included and those investigated the cervical dysplasia, cervical intraepithelial neoplasia (CIN), or cervical squamous intraepithelial lesions (CSIL) were excluded. Thus, the study by Taskiran et al. was not included in this meta-analysis (Taskiran et al., 2006). After data syntheses, we found a borderline correlation of CYP1A1 Ile462Val polymorphism with the susceptibility to cervical cancer in total analysis. And the polymorphism significantly elevated the risk in Caucasian and population-based groups after subgroup analyses by ethnicity and source of control. Sensitivity analysis was conducted to evaluate the influence of individual study on overall analysis, which indicated that the overall results were robust. Furthermore, assessment of publication bias was confirmed by visual inspection of funnel plots and Egger’s test, supporting that publication bias across the studies was negligible. Cumulative meta-analysis was also carried out to observe the change when with sample sizes were enlarged, and the CIs became increasing narrower. Recently, the relationships between some other polymorphisms and cervical cancer development were investigated, such as CYP1A1 MspI (rs4646903), COMT
Ile462Val polymorphism is in tight linkage disequilibrium with the MspI polymorphism, and these variant genotypes are associated with greater CYP1A1 activity or inducibility (Crofts et al., 1994; Ng et al., 2005). Thus, the borderline association between Ile462Val polymorphism and cervical cancer risk cannot be excluded and may indicate a role of this variant, which warrants further functional studies.

Despite certain advantages, there still were some limitations to be addressed. To begin with, the sample sizes of subgroup analyses were relatively small, which might affect the final results. Second, since meta-analysis is a secondary analysis (Zeng et al., 2015), the possible impacts of gene-gene and gene-environment interactions with this polymorphism on cervical cancer susceptibility were not evaluated due to insufficient information from original papers. Third, only studies published in English or Chinese language were included, some unpublished due to negative findings or other reasons and in other languages might be missed.

In summary, our meta-analysis outcomes revealed a borderline relationship between CYP1A1 Ile462Val polymorphism and cervical cancer risk in general population, and this polymorphism significantly increase the risk in Caucasian females. It provides an important theoretical basis to reveal the CYP1A1 Ile462Val polymorphism and the biological mechanism of developing cervical cancer, which may be helpful to predict the occurrence of cervical cancer in Caucasian females. Importantly, special attention should be paid upon the design of future studies, such as selection of subjects and adjustment of interfering factors so as to uncover any underlying mechanisms and distinct patterns. In view of the above mentioned restrictions, these results should be applied with prudence and further verified by large-scale and well-designed studies with various ethnic groups.

AUTHOR CONTRIBUTIONS

L-NW and X-QR designed this study; FW and Y-HJ searched databases and collected full-text papers; JL and CF extracted and analyzed data; L-NW, FW, and JL wrote the manuscript, X-QR reviewed the manuscript.

REFERENCES

Abbas, M., Srivastava, K., Imran, M., and Banerjee, M. (2014). Association of CYP1A1 gene variants rs4646903 (T>C) and rs1048943 (A>G) with cervical cancer in a North Indian population. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 176, 68–74. doi: 10.1016/j.ejogrb.2014.02.036

Crofts, F., Taioi, E., Trachman, J., Cosma, G. N., Currie, D., Toniolo, P., et al. (1994). Functional significance of different human CYP1A1 genotypes. *Carcinogenesis* 15, 2961–2963. doi: 10.1093/carcin/15.12.2961

Denslow, S. A., Knop, G., Klaus, C., Brewer, N. T., Rao, C., and Smith, J. S. (2012). Burden of invasive cervical cancer in North Carolina. *Prev. Med.* 54, 3–4. doi: 10.1016/j.ympmed.2012.01.020

Ding, F. Y., Ma, G. F., Song, X. H., Shi, W. H., Lan, J. Y., and Yu, H. Y. (2011). Relationship between CYP1A1 gene polymorphism and genetic susceptibility of cervical carcinoma. *Jiangsu Med.* J. 37, 2562–2564.

Forouzanfar, M. H., Foreman, K. J., Delossantos, A. M., Lopez, A. D., Murray, C. J., et al. (2011). Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. *Lancet* 378, 1461–1484. doi: 10.1016/S0140-6736(11)61351-2

Geng, J., Shi, Y. R., Wang, H., and Qin, R. (2010). Research of cytochrome P450 1A1 Ile/Val polymorphism and genetic susceptibility in cervical cancer. *J. Bengbu Med. Coll.* 35, 762–767.

Gutman, G., Morad, T., Peleg, B., Peretz, C., Bar-Am, A., Safra, T., et al. (2009). CYP1A1 and CYP2D6 gene polymorphisms in Israeli Jewish women with cervical cancer. *Int. J. Gynecol. Cancer* 19, 1300–1302. doi: 10.1111/j.1525-1317.2008.01351.x

Huang, Y. K., Hsieh, H. C., Sun, J. A., Chao, C. F., Huang, R. L., Lai, H. C., et al. (2006). Genetic polymorphisms of phase I and phase II xenobiotic enzymes in human papillomavirus related lesion and cancer of the uterine cervix. *Tai Chi Med. J.* 18, 267-274+328.

Joseph, T., Chacko, P., Wesley, R., Jayaprakash, P. G., James, F. V., and Pillai, M. R. (2006). Germline genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes in Indian cervical cancer: associations with tumor progression, age and human papillomavirus infection. *Gynecol. Oncol.* 101, 411–417. doi: 10.1016/j.ygyno.2005.10.033

Li, S., Li, G., Kong, F., Liu, Z., Li, N., Li, Y., et al. (2016). The association of CYP1A1 gene with cervical cancer and additional SNP-SNP interaction in chinese women. *J. Clin. Lab. Anal.* 30, 1220–1225. doi: 10.1002/jcla.22006

Matos, A., Castelao, C., Pereira da Silva, A., Alho, I., Bicho, M., Medeiros, R., et al. (2016). Epistatic Interaction of CYP1A1 and COMT Polymorphisms In Cervical Cancer. *Oxid. Med. Cell. Longev.* 2016:2769804. doi: 10.1155/2016/2769804

Ng, D. P., Tan, K. W., Zhao, B., and Seow, A. (2005). CYP1A1 polymorphisms and risk of lung cancer in non-smoking Chinese women: influence of environmental tobacco smoke exposure and GSTM1/T1 genetic variation. *Cancer Causes Control* 16, 399–405. doi: 10.1007/s10552-004-5476-0

Pabalan, N. A. (2010). Meta-analysis in cancer genetics. *Asian Pac. J. Cancer Prev.* 11, 33–38.

Patel, H., Jee, Y. B., Sherman, S. M., and Moss, E. L. (2016). Knowledge of human papillomavirus and the human papillomavirus vaccine in European adolescents: a systematic review. *Sex. Transm. Infect.* 92, 474–479. doi: 10.1136/sextrans-2015-052341

Qin, J., Zhang, J. X., Li, X. P., Wu, B. Q., Chen, G. B., and He, X. F. (2014). Association between the CYP1A1 A2455G polymorphism and risk of cancer: evidence from 272 case-control studies. *Tumour Biol.* 35, 3363–3376. doi: 10.1007/s13277-013-1443-2

Rodriguez-Antona, C., Gomez, A., Karlgren, M., Sim, S. C., and Ingelman-Sundberg, M. (2010). Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. *Hum. Genet.* 127, 1–17. doi: 10.1007/s00439-009-0748-0

Roszak, A., Laineri, M., Sowinski, A., and Jagodziński, P. P. (2014). CYP1A1 Ile462Val polymorphism as a risk factor in cervical cancer development in the Polish population. *Mol. Diagn. Ther.* 18, 445–450. doi: 10.4029/mdt-014-0099-2

Rotondi, M. A., and Bull, S. B. (2012). Cumulative meta-analysis for genetic association: when is a new study worthwhile? *Hum. Hered.* 74, 61–70. doi: 10.1159/000345604

Sergentanis, T. N., Economopoulos, K. P., Choussen, S., and Vlahos, N. F. (2012). Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and cervical cancer risk: a meta-analysis. *Mol. Biol. Rep.* 39, 6647–6654. doi: 10.1007/s11033-012-1470-x

Shi, Y. R., Geng, J., Cheng, L. Q., Wang, H., and Zhang, Y. G. (2011). Association of Cytochrome P450 1A1 gene polymorphisms with cervical cancer. *Fudan Univ. J. Med. Sci.* 38, 428–431. doi: 10.3969/j.issn.1672-8467.2011.05.010

Sood, A. K. (1991). Cigarette smoking and cervical cancer: meta-analysis and critical review of recent studies. *Am. J. Prev. Med.* 7, 208–213.
Sugawara, T., Nomura, E., Sagawa, T., Sakuragi, N., and Fujimoto, S. (2003). CYP1A1 polymorphism and risk of gynecological malignancy in Japan. *Int. J. Gynecol. Cancer* 13, 785–790. doi: 10.1111/j.1525-1438.2003.13607.x

Taskiran, C., Aktas, D., Yigit-Celik, N., Alikasifoglu, M., Yuce, K., Tunçbilek, E., et al. (2006). CYP1A1 gene polymorphism as a risk factor for cervical intraepithelial neoplasia and invasive cervical cancer. *Gynecol. Oncol.* 101, 503–506. doi: 10.1016/j.ygyno.2005.11.018

Von, K. H., Bergmann, T., Schuetz, M., Schiller, U., Stanke, J., Hoffmann, C., et al. (2011). Analysis of 4 single-nucleotide polymorphisms in relation to cervical dysplasia and cancer development using a high-throughput ligation-detection reaction procedure. *Int. J. Gynecol. Cancer* 21, 1664–1671. doi: 10.1097/IGC.0b013e31822b6299

Wang, S., Sun, H., Jia, Y., Tang, F., Zhou, H., Li, X., et al. (2015). Association of 42 SNPs with genetic risk for cervical cancer: an extensive meta-analysis. *BMC Med. Genet.* 16:25. doi: 10.1186/s12881-015-0168-z

Wang, S., Sun, H., Jia, Y., Tang, F., Zhou, H., Li, X., et al. (2015). Association of 42 SNPs with genetic risk for cervical cancer: an extensive meta-analysis. *BMC Med. Genet.* 16:25. doi: 10.1186/s12881-015-0168-z

Wu, B., Liu, K., Huang, H., Yuan, J., Yuan, W., Wang, S., et al. (2013). MspI and Ile462Val polymorphisms in CYP1A1 and overall cancer risk: a meta-analysis. *PLoS ONE* 8:e85166. doi: 10.1371/journal.pone.0085166

Yang, S., Jia, C., Zhu, H., and Han, S. (2012). CYP1A1 Ile462Val polymorphism and cervical cancer: evidence from a meta-analysis. *Tumour Biol.* 33, 2265–2272. doi: 10.1007/s13277-012-0488-y

Zeng, X. T., Xiong, P. A., Wang, F., Li, C. Y., Yao, J., and Guo, Y. (2012). Passive smoking and cervical cancer risk: a meta-analysis based on 3,230 cases and 2,982 controls. *Asian Pac. J. Cancer Prev.* 13, 2687–2693. doi: 10.7314/APJCP.2012.13.6.2687

Zeng, X., Zhang, Y., Kwong, J. S., Zhang, C., Li, S., Sun, F., et al. (2015). The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. *J. Evid. Based Med.* 8, 2–10. doi: 10.1111/jebm.12141

Zhang, S. H. (2009). *Polymorphisms of Cyp1a1 Gene and HPV Infection of Cervical Squamous Carcinoma*. Master of Medicine Master’s thesis, Taishan Medical University.

Zhang, X. (2011). P450 1A1 gene polymorphism and cervical cancer IleVal Correlation. *Jilin Med. J.* 32, 419–420. doi: 10.3969/j.issn.1004-0412.2011.03.001

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Wang, Wang, Liu, Jin, Fang and Ren. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.